Disease · MONDO_0004967
Comparisons in its trials109
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 109
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| Dasatinib 140 mg QD vs Dasatinib 70 mg BID: serious adverse events | 228 of 304 | 236 of 305 | 609 | NCT00123487 | Trial comparisons |
| CML-CP With Prior Imatinib Only vs CML-AP With Prior Imatinib Only: Participants With (MMR) Major Molecular Response (Phase II) | 106 of 299 | 18 of 122 | 421 | NCT00109707 | Trial comparisons |
| Blinatumomab vs Standard of Care Chemotherapy: serious adverse events | 165 of 267 | 49 of 109 | 376 | NCT02013167 | Trial comparisons |
| Inotuzumab Ozogamicin vs Defined Investigator's Choice of Chemotherapy: serious adverse events | 85 of 164 | 72 of 143 | 307 | NCT01564784 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease | 2 of 13 | 79 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Serious Adverse Events | 0 of 13 | 47 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Overall Survival | 8 of 13 | 181 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Transplant Related Mortality | 2 of 13 | 40 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: deaths from any cause | 6 of 13 | 124 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Neutrophil and Donor Cell Engraftment | 12 of 13 | 289 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: serious adverse events | 1 of 13 | 53 of 292 | 305 | NCT00303719 | Trial comparisons |
| Phase I - Alemtuzumab and Combination Chemotherapy vs Phase II - Alemtuzumab and Combination Chemotherapy: serious adverse events | 60 of 119 | 98 of 181 | 300 | NCT00061945 | Trial comparisons |
| Phase I - Alemtuzumab and Combination Chemotherapy vs Phase II - Alemtuzumab and Combination Chemotherapy: Number of Participants Achieving Complete Remission | 92 of 116 | 145 of 181 | 297 | NCT00061945 | Trial comparisons |
| Regimen A: Standard Vincristine Dosing vs Arm B: Randomized High Dose Vincristine Regimen: serious adverse events | 40 of 203 | 11 of 68 | 271 | NCT00381680 | Trial comparisons |
| Cohort A: Ponatinib 30 mg vs Cohort B: Imatinib 600 mg: deaths from any cause | 21 of 163 | 13 of 81 | 244 | NCT03589326 | Trial comparisons |
| Cohort A: Ponatinib 30 mg vs Cohort B: Imatinib 600 mg: serious adverse events | 97 of 163 | 45 of 81 | 244 | NCT03589326 | Trial comparisons |
| SC-PEG (Arm A) vs Oncaspar (Arm B): deaths from any cause | 7 of 119 | 5 of 120 | 239 | NCT01574274 | Trial comparisons |
| SC-PEG (Arm A) vs Oncaspar (Arm B): serious adverse events | 35 of 119 | 27 of 120 | 239 | NCT01574274 | Trial comparisons |
| Cohort A: Ponatinib 30 mg vs Cohort B: Imatinib 600 mg: Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase | 53 of 154 | 13 of 78 | 232 | NCT03589326 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004967/comparisons